Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)

NCT03207945 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

118

Enrollment

OTHER

Sponsor class

Conditions

Dyslipidemias
Cardiovascular Diseases
HIV Infections

Interventions

DRUG: Alirocumab
OTHER: Placebo

Sponsor

University of California, San Francisco

Collaborators

[object Object]